Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence Corey, Myron S. Cohen, Fatima Laher et al.|New England Journal of Medicine|2021Cited by 540
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in AdultsGlenda Gray, Lubbe Wiesner, Linda‐Gail Bekker et al.|New England Journal of Medicine|2021Cited by 231
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trialKenneth H. Mayer, Kelly E. Seaton, Yunda Huang et al.|PLoS Medicine|2017Cited by 132
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Catherine Orrel, Jessica E. Long et al.|JAMA Network Open|2023Cited by 38
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan Buchbinder, Nicole Grunenberg, Brittany Sanchez et al.|PLoS ONE|2017Cited by 33